Table 3.
Response to pazopanib based on histologic subtypes (the percentage of response is indicated for LMS, UPS, and all cases).
| Histology | CR | PR | SD | PD | Total |
|---|---|---|---|---|---|
| Alveolar rhabdomyosarcoma | 1 | 1 | |||
| ASPS | 1 | 1 | |||
| Angiomatoid histiocytoma | 1 | 1 | |||
| Angiosarcoma | 1 | 1 | 2 | 4 | |
| Chondrosarcoma | 3 | 5 | 8 | ||
| Chordoma | 1 | 1 | |||
| Dedifferentiated liposarcoma | 1 | 4 | 5 | ||
| Desmoplastic small round cell tumor | 3 | 3 | |||
| Epithelioid hemangioendothelioma | 1 | 1 | |||
| Ewing’s sarcoma | 2 | 1 | 3 | ||
| Endometrial stromal tumor | 1 | 1 | |||
| Hemangiopericytoma | 1 | 1 | 2 | ||
| Leiomyosarcoma | 4 (10%) | 9 (22.5%) | 27 (67.5%) | 40 | |
| Low grade fibromyxoid sarcoma | 1 | 1 | |||
| Malignant peripheral nerve sheath tumor | 4 | 3 | 7 | ||
| Malignant phyllodes | 1 | 1 | |||
| Myxoid liposarcoma | 1 | 1 | |||
| Osteosarcoma | 2 | 4 | 6 | ||
| Pleomorphic liposarcoma | 1 | 1 | 1 | 3 | |
| Pleomorphic rhabdomyosarcoma | 2 | 1 | 3 | ||
| PeComa | 1 | 1 | |||
| Synovial sarcoma | 4 | 3 | 7 | ||
| UPS | 3 (13.6%) | 5 (22.7%) | 14 (63.6%) | 22 | |
| Total cases | N = 1 (0.8%) | N = 12 (9.7%) | N = 34 (27.6%) | N = 76 (61.8%) | N = 123 (100%) |